On October 22, 2019, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and COUR Pharmaceutical Development Company, Inc. (“COUR”) announced that Takeda has acquired an exclusive global license to develop and commercialize the investigational medicine CNP-101/TAK-101, an immune-modifying nanoparticle containing gliadin proteins. Based on COUR’s antigen-specific immune tolerance platform, TAK-101 is a potential first-in-class treatment targeting the aberrant immune response in celiac disease, a serious autoimmune disease where the ingestion of gluten leads to inflammation and damage in the small intestine. Results of a randomized, double-blind, placebo-controlled clinical trial to assess the markers of potential efficacy and safety of the investigational medicine in 34 adults with proven celiac disease was presented on October 22, 2019 as a late-breaking abstract at UEG Week 2019, Barcelona, Spain (https://live.ueg.eu/week/). At inclusion, patients had well-controlled, biopsy-proven celiac disease. After inclusion, they underwent an oral gluten challenge. Based on the study, Takeda exercised its option to acquire the exclusive global license to TAK-101. “While many people living with celiac disease can manage their symptoms by following a gluten-free diet, there are currently no treatment options for those who continue to have symptoms,” said Asit Parikh MD, PhD, Head, Gastroenterology Therapeutic Area Unit at Takeda. “Our collaboration with COUR has shown, for the first time, that it is possible to induce specific immune tolerance to a foreign antigen in autoimmune diseases such as celiac disease.
Login Or Register To Read Full Story